Dominik Paul Modest

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Cetuximab Versus Folfiri, Oncology, Clinical Trials +9

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius et al. · The Lancet Oncology · 2016 · 410 citations

Cetuximab Versus Folfiri, Gastrointestinal Oncology, Tumour Dynamics +10

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Gerald W. Prager, Marwan Fakih, Fortunato Ciardiello et al. · New England Journal of Medicine · 2023 · 375 citations · Full text

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Ingrid Ricard, Volker Heinemann et al. · Annals of Oncology · 2016 · 334 citations · Full text

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C

Marwan Fakih, Lisa Salvatore, Taito Esaki et al. · New England Journal of Medicine · 2023 · 294 citations